213 related articles for article (PubMed ID: 37164603)
1. Long-Term Outcome of Drug-Coated Balloon vs Drug-Eluting Stent for Small Coronary Vessels: PICCOLETO-II 3-Year Follow-Up.
Cortese B; Testa G; Rivero F; Erriquez A; Alfonso F
JACC Cardiovasc Interv; 2023 May; 16(9):1054-1061. PubMed ID: 37164603
[TBL] [Abstract][Full Text] [Related]
2. Drug-Coated Balloon Versus Drug-Eluting Stent for Small Coronary Vessel Disease: PICCOLETO II Randomized Clinical Trial.
Cortese B; Di Palma G; Guimaraes MG; Piraino D; Orrego PS; Buccheri D; Rivero F; Perotto A; Zambelli G; Alfonso F
JACC Cardiovasc Interv; 2020 Dec; 13(24):2840-2849. PubMed ID: 33248978
[TBL] [Abstract][Full Text] [Related]
3. A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions.
Yu X; Wang X; Ji F; Zhang W; Yang C; Xu F; Wang F
Cardiovasc Drugs Ther; 2022 Aug; 36(4):655-664. PubMed ID: 33713211
[TBL] [Abstract][Full Text] [Related]
4. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
6. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
7. A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels.
Giannini F; Latib A; Ancona MB; Costopoulos C; Ruparelia N; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Colombo A
Catheter Cardiovasc Interv; 2017 Sep; 90(3):380-386. PubMed ID: 28109036
[TBL] [Abstract][Full Text] [Related]
8. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.
Jeger RV; Farah A; Ohlow MA; Mangner N; Möbius-Winkler S; Weilenmann D; Wöhrle J; Stachel G; Markovic S; Leibundgut G; Rickenbacher P; Osswald S; Cattaneo M; Gilgen N; Kaiser C; Scheller B;
Lancet; 2020 Nov; 396(10261):1504-1510. PubMed ID: 33091360
[TBL] [Abstract][Full Text] [Related]
10. Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial.
Wöhrle J; Scheller B; Seeger J; Farah A; Ohlow MA; Mangner N; Möbius-Winkler S; Weilenmann D; Stachel G; Leibundgut G; Rickenbacher P; Cattaneo M; Gilgen N; Kaiser C; Jeger RV;
JACC Cardiovasc Interv; 2021 Aug; 14(16):1789-1798. PubMed ID: 34412797
[TBL] [Abstract][Full Text] [Related]
11. Clinical Impact of Drug-Coated Balloon-Based Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease.
Shin ES; Jun EJ; Kim S; Kim B; Kim TH; Sohn CB; Her AY; Park Y; Cho JR; Jeong YH; Choi BJ
JACC Cardiovasc Interv; 2023 Feb; 16(3):292-299. PubMed ID: 36609038
[TBL] [Abstract][Full Text] [Related]
12. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
[TBL] [Abstract][Full Text] [Related]
13. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial.
Giacoppo D; Alvarez-Covarrubias HA; Koch T; Cassese S; Xhepa E; Kessler T; Wiebe J; Joner M; Hochholzer W; Laugwitz KL; Schunkert H; Kastrati A; Kufner S
Eur Heart J; 2023 Apr; 44(15):1343-1357. PubMed ID: 36807512
[TBL] [Abstract][Full Text] [Related]
14. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2.
Mangner N; Farah A; Ohlow MA; Möbius-Winkler S; Weilenmann D; Wöhrle J; Linke A; Stachel G; Markovic S; Leibundgut G; Rickenbacher P; Cattaneo M; Gilgen N; Kaiser C; Scheller B; Jeger RV;
Circ Cardiovasc Interv; 2022 Feb; 15(2):e011325. PubMed ID: 35000455
[TBL] [Abstract][Full Text] [Related]
17. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
[TBL] [Abstract][Full Text] [Related]
19. Drug-coated balloon strategy following orbital atherectomy for calcified coronary artery compared with drug-eluting stent: One-year outcomes and optical coherence tomography assessment.
Mitsui K; Lee T; Miyazaki R; Hara N; Nagamine S; Nakamura T; Terui M; Okata S; Nagase M; Nitta G; Watanabe K; Kaneko M; Nagata Y; Nozato T; Ashikaga T
Catheter Cardiovasc Interv; 2023 Jul; 102(1):11-17. PubMed ID: 37210618
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
